Gensight Biologics Sa Stock Fundamentals
| SIGHT Stock | EUR 0.32 0.01 3.23% |
Gensight Biologics SA fundamentals help investors to digest information that contributes to Gensight Biologics' financial success or failures. It also enables traders to predict the movement of Gensight Stock. The fundamental analysis module provides a way to measure Gensight Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gensight Biologics stock.
Gensight |
Gensight Biologics SA Company Return On Equity Analysis
Gensight Biologics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Gensight Biologics Return On Equity | -1.72 |
Most of Gensight Biologics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gensight Biologics SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Gensight Biologics SA has a Return On Equity of -1.719. This is 92.83% lower than that of the Biotechnology sector and 95.29% lower than that of the Health Care industry. The return on equity for all France stocks is notably higher than that of the company.
Gensight Biologics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Gensight Biologics's current stock value. Our valuation model uses many indicators to compare Gensight Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Gensight Biologics competition to find correlations between indicators driving Gensight Biologics's intrinsic value. More Info.Gensight Biologics SA is rated third in return on equity category among its peers. It is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Gensight Biologics' earnings, one of the primary drivers of an investment's value.Gensight Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gensight Biologics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gensight Biologics could also be used in its relative valuation, which is a method of valuing Gensight Biologics by comparing valuation metrics of similar companies.Gensight Biologics is currently under evaluation in return on equity category among its peers.
Gensight Fundamentals
| Return On Equity | -1.72 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (6.59) % | |||
| Current Valuation | 150.19 M | |||
| Shares Outstanding | 46.16 M | |||
| Shares Owned By Insiders | 12.75 % | |||
| Shares Owned By Institutions | 35.65 % | |||
| Price To Book | 50.99 X | |||
| Price To Sales | 33.81 X | |||
| Revenue | 5.28 M | |||
| Gross Profit | 7.71 M | |||
| EBITDA | (25.52 M) | |||
| Net Income | (28.62 M) | |||
| Cash And Equivalents | 44.29 M | |||
| Cash Per Share | 1.06 X | |||
| Total Debt | 12.1 M | |||
| Debt To Equity | 14.40 % | |||
| Current Ratio | 3.65 X | |||
| Book Value Per Share | 0.07 X | |||
| Cash Flow From Operations | (17.14 M) | |||
| Earnings Per Share | (0.68) X | |||
| Target Price | 9.8 | |||
| Number Of Employees | 44 | |||
| Beta | 2.16 | |||
| Market Capitalization | 144.58 M | |||
| Total Asset | 56.65 M | |||
| Z Score | 6.6 | |||
| Net Asset | 56.65 M |
About Gensight Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gensight Biologics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gensight Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gensight Biologics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. GenSight Biologics S.A. was founded in 2012 and is headquartered in Paris, France. GENSIGHT BIOLOGICS is traded on Paris Stock Exchange in France.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Gensight Stock Analysis
When running Gensight Biologics' price analysis, check to measure Gensight Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gensight Biologics is operating at the current time. Most of Gensight Biologics' value examination focuses on studying past and present price action to predict the probability of Gensight Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gensight Biologics' price. Additionally, you may evaluate how the addition of Gensight Biologics to your portfolios can decrease your overall portfolio volatility.